Business Description
Clarus Therapeutics Holdings Inc
NAICS : 325412
SIC : 2834
555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062
Description
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.24 | |||||
| Equity-to-Asset | -0.83 | |||||
| Debt-to-Equity | -1.27 | |||||
| Debt-to-EBITDA | -2.83 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | -15.51 | |||||
| Beneish M-Score | 0 | |||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.94 | |||||
| 9-Day RSI | 53.32 | |||||
| 14-Day RSI | 46.51 | |||||
| 6-1 Month Momentum % | -71.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.55 | |||||
| Quick Ratio | 0.33 | |||||
| Cash Ratio | 0.14 | |||||
| Days Inventory | 2056.13 | |||||
| Days Sales Outstanding | 201.32 | |||||
| Days Payable | 2165.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 80.85 | |||||
| Operating Margin % | -227.47 | |||||
| Net Margin % | -170.63 | |||||
| ROA % | -49.29 | |||||
| ROIC % | -67.43 | |||||
| ROC (Joel Greenblatt) % | -2495.05 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.3 | |||||
| EV-to-EBIT | -3.49 | |||||
| EV-to-EBITDA | -3.5 | |||||
| EV-to-Revenue | 3.68 | |||||
| EV-to-Forward-Revenue | 2.03 | |||||
| EV-to-FCF | -1.73 | |||||
| Earnings Yield (Greenblatt) % | -28.71 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:CRXT
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 12.859 | ||
| EPS (TTM) ($) | -1.06 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 46.51 | ||
| 14-Day ATR ($) | 0.029202 | ||
| 20-Day SMA ($) | 0.313178 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 0.2605 - 9.77 | ||
| Shares Outstanding (Mil) | 52.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Clarus Therapeutics Holdings Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||